(unaudited)

 
Condensed 
Statements of           Three Months Ended           Nine Months Ended 
Operations Data            September 30,               September 30, 
                     -------------------------   ------------------------- 
                        2024          2023          2024          2023 
                     -----------   -----------   -----------   ----------- 
Revenue              $    --       $    --       $    --       $    -- 
Operating 
expenses: 
   Research and 
    development          535,162       374,200     1,214,964     1,429,757 
   General and 
    administrative     1,766,010       900,089     3,470,133     2,879,036 
                      ----------    ----------    ----------    ---------- 
      Total 
       operating 
       expenses        2,301,172     1,274,289     4,685,097     4,308,793 
                      ----------    ----------    ----------    ---------- 
Loss from 
 operations           (2,301,172)   (1,274,289)   (4,685,097)   (4,308,793) 
Other Income: 
   Interest income        20,488        39,215        63,245       115,951 
                      ----------    ----------    ----------    ---------- 
   Total Other 
    income                20,488        39,215        63,245       115,951 
                      ----------    ----------    ----------    ---------- 
Net loss             $(2,280,684)  $(1,235,074)  $(4,621,852)  $(4,192,842) 
                      ==========    ==========    ==========    ========== 
Net loss per share 
 of common stock -- 
 basic and diluted, 
 as adjusted         $     (2.05)  $     (1.62)  $     (4.95)  $     (5.63) 
                      ==========    ==========    ==========    ========== 
Weighted average 
 shares outstanding 
 -- basic and 
 diluted, as 
 adjusted              1,110,317       763,750       932,872       774,586 
                      ==========    ==========    ==========    ========== 
 
 
 
Condensed Balance Sheet Data    September 30,    December 31, 
                                    2024             2023 
                               ---------------  -------------- 
 
Cash                            $    2,039,819   $   3,316,946 
Total assets                         2,283,249       4,165,442 
Total liabilities                    1,333,818         358,548 
Total stockholders' equity             949,431       3,806,894 
 
 

Source: Dogwood Therapeutics, Inc.

(END) Dow Jones Newswires

November 07, 2024 07:05 ET (12:05 GMT)